SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-047073
Filing Date
2024-02-27
Accepted
2024-02-27 07:30:53
Documents
16
Period of Report
2024-02-27
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d796432d8k.htm   iXBRL 8-K 29286
2 EX-99.1 d796432dex991.htm EX-99.1 133709
6 GRAPHIC g796432g0227061838075.jpg GRAPHIC 1745
  Complete submission text file 0001193125-24-047073.txt   304398

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA apls-20240227.xsd EX-101.SCH 2850
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE apls-20240227_lab.xml EX-101.LAB 17235
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apls-20240227_pre.xml EX-101.PRE 10812
17 EXTRACTED XBRL INSTANCE DOCUMENT d796432d8k_htm.xml XML 3475
Mailing Address 100 FIFTH AVENUE WALTHAM MA 02451
Business Address 100 FIFTH AVENUE WALTHAM MA 02451 617-977-5700
Apellis Pharmaceuticals, Inc. (Filer) CIK: 0001492422 (see all company filings)

IRS No.: 271537290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38276 | Film No.: 24681991
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)